Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders-Reference-Cited by-同舟云学术

Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders

Published:2020-12-16 Issue:1 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Calcagno Andrea¹^ORCID,Dal Conte Ivano²,Cattaneo Dario³,Testi Roberto²,Mistrangelo Massimiliano⁴,Gervasoni Cristina⁵,de Nicolò Amedeo⁶,Bonora Stefano¹,D’Avolio Antonio⁶^ORCID,Di Perri Giovanni¹

Affiliation:

1. Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy

2. Sexual Health Centre, Department of Prevention, ASL Città di Torino, Turin, Italy

3. Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy

4. Department of Surgical Sciences, University of Turin, Turin, Italy

5. Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy

6. Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Turin, Italy

Abstract

Four pre-exposure prophylaxis (PrEP) users with gastrointestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease, or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite self-reported high adherence, trough plasma tenofovir concentrations (after supervised intake) were significantly lower in these patients than in PrEP recipients without gastrointestinal disorders (21 ± 9.1 versus 138 ± 85 ng/ml). PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01902-20

Reference28 articles.

1. Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline

2. Fall in new HIV diagnoses among men who have sex with men (MSM) at selected London sexual health clinics since early 2015: testing or treatment or pre-exposure prophylaxis (PrEP)?;Brown AE;Euro Surveill,2017

3. Predictive factors for HIV infection among men who have sex with men and who are seeking PrEP: a secondary analysis of the PROUD trial

4. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

5. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions;Expert Review of Clinical Pharmacology;2024-06-04

2. Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus;Nature Reviews Gastroenterology & Hepatology;2024-05-19

3. Belgian 2024 guidance on the use of pre-exposure prophylaxis;Acta Clinica Belgica;2024-03-03

4. Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV;Clinical Pharmacokinetics;2022-04-11

5. Conference proceedings from the 23rd Bangkok International Symposium on HIV Medicine;Future Virology;2021-04